Tag: research

  • STAT+: Scientists made mice with half a brain. Then they filled them with human organoids

    STAT+: Scientists made mice with half a brain. Then they filled them with human organoids

    For the last decade, scientists have been steadily getting better at growing “cerebral organoids,”  miniature, three-dimensional brain-like structures, from human stem cells in the lab. Now, a group from Stanford University has found a way to advance their usefulness for studying brain development and disease — by instead growing them inside mice that have had large parts of their own brains genetically removed. 

    Neuroscientists say these “neuro-chimeric” mice, whose brains are half-human — by volume, not by number of neurons — are an important innovation for a field hampered by longstanding challenges in accessing human brain tissue for research. But such models also raise a host of ethical questions that will get thornier the more advanced they become. 

    In a study published Wednesday in Nature, the Stanford team reported finding types of human cells inside the brains of 3-month-old chimeric mouse pups that are very hard to obtain in a dish. They included pyramidal projection neurons that had wound their way into some of the animals’ spinal cords. The scientists also found evidence of specialized, super-sized neurons involved in social cognition only found in large-brain mammals like elephants, whales, and primates, including humans. 

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • Judge blocks Trump administration plans to limit visa length for grad students, postdocs

    Judge blocks Trump administration plans to limit visa length for grad students, postdocs

    A federal judge on Monday issued a preliminary injunction blocking the Trump administration from upending a long-standing policy that allows foreign students and scholars to stay in the U.S. for the duration of their training, a decision that suggests that plaintiffs opposed to the policy change are likely to ultimately succeed.

    The ruling halts plans by the Department of Homeland Security to place a four-year cap on the kinds of visas used by graduate students and postdoctoral researchers while a judge hears full arguments in a lawsuit over the new policy. Experts warn the outcome of the case could have a dramatic impact on the nation’s biomedical preeminence given that international researchers make up a large share of the U.S. life science workforce. The new policy had been set to take effect on Tuesday. 

    In his ruling, Judge F. Dennis Saylor IV of the U.S. District Court for the District of Massachusetts wrote that “the promulgation of the rule clearly failed to comply with the [Administrative Procedure Act].” Saylor added that the administration’s argument that the new visa policy is needed to safeguard national security was weak and “raises legitimate questions as to whether its real purpose is not to safeguard national security and protect our borders, but to achieve other, undisclosed, goals — such as, for example, asserting greater government control over academic institutions.” 

    While Saylor said that the plaintiffs have a “substantial likelihood of success” in the case, he declined to issue a summary judgment definitively striking down the DHS rule.

    In a Sept. 3 hearing, an attorney for the coalition of academic groups that challenged the visa restrictions, Paul Hughes from the firm McDermott, Will & Schulte, argued the government did not conduct a sufficient analysis of the fallout of the new policy. Without a delay in its implementation or throwing out the change, he said schools would experience “irreparable harm.” 

    Michael Celone, a Department of Justice lawyer, in turn, argued that the government had done its due diligence and that the plaintiffs had not demonstrated tangible harm that would result from the policy. Celone said students who are impacted by the policy could either apply for extensions or easily apply elsewhere, comparing students choosing schools to taking a book out of the library. 

    Saylor seemed skeptical of the government’s reasoning, questioning how the policy would diminish any national security risks posed by international students. “I am struggling to see any real, rational connection between national security issues identified, which is not even half of a dozen incidents over 50 years, and this change,” he said to Celone during the hearing. 

    The judge also took issue with the relatively short time the policy was open for public comments: “Can I say it’s illegal? Probably not. But it is part of the mix here to what extent the government was taking its duty seriously in weighing costs and benefits.”

    Academic groups, including the nonprofit NAFSA: Association of International Educators and the Presidents’ Alliance on Higher Education and Immigration, have joined the suit. DHS; Markwayne Mullin, secretary of the department; U.S. Immigration and Customs Enforcement; and David Venturella, acting director of ICE, are named as defendants.

    The case centers around a long-standing policy known as duration of status, which for more than 40 years has allowed international students and scholars to remain in the U.S. for however long it took them to complete their training. 

    The federal government implemented the policy in 1979 to streamline international students’ admission into the country. But the Trump administration has argued duration of status has led to the creation of “forever students,” whom they allege cheat the system by perpetually enrolling in courses to avoid leaving the U.S.

    In mid-July, DHS announced that, going forward, foreign students and postdocs won’t be allowed to stay in the U.S. for more than four years on nonimmigrant visas unless they apply for and receive an extension. Students and postdocs already in the U.S. wouldn’t need to apply for extensions if their training will end before September 2030.

    But in a suit filed in mid-August, the academic groups alleged that the new rules violate the Administrative Procedure Act, a law that governs how agencies implement new regulations. The plaintiffs alleged that DHS didn’t give interested parties enough time to comment on the new rule, didn’t respond substantively to comments, and hasn’t clearly explained why the new policy is a rational and necessary response to alleged visa fraud.

    The academic coalition warned in the suit that uncertainty around whether foreign researchers will be able to stay in the U.S. for the length of their training could prevent them from coming here in the first place. A NAFSA poll of more than 1,000 current students and postdocs found that nearly half of them would not have come to the U.S. under a fixed period of admission.

    In its response, the Trump administration dismissed the findings of the poll as “uncertain and speculative.” The government also argued that the new rule was necessary to safeguard national security and would have minimal downside, and that if international enrollment does decline, it could be for reasons unrelated to the end of duration of status.

    International researchers make up nearly a quarter of life science Ph.D. graduates and around 60% of postdoctoral researchers. The new policy would mean many of them would need to apply for a visa extension; the average biomedical Ph.D. takes five to six years to complete, and National Science Foundation data indicate that about a fifth of postdocs have worked in that role for more than six years.

    STAT’s coverage of the federal government’s impact on the biomedical workforce is supported by a grant from the Dana Foundation and the Boston Foundation. Our financial supporters are not involved in any decisions about our journalism.

  • Platinum-based chemotherapy in childhood causes mutations that age the liver

    Platinum-based chemotherapy in childhood causes mutations that age the liver

    Platinum-based chemotherapy — in particular cisplatin and carboplatin — are a lifeline for children with certain cancers. These treatments, for instance, transformed the prognosis of hepatoblastoma, a rare cancer of the liver that is the most commonly diagnosed in childhood, from a five-year survival rate of 20% to more than 80% for localized tumors. 

    However, these medications work by damaging the DNA of cancer cells, and they are also known to cause mutations in the DNA of healthy cells, potentially raising the risk of new cancers later in life. The mutations have been documented in adults, but the picture is less clear when it comes to children. A new study published Thursday in Science sought a clearer understanding of the long-term impact of platinum agents in children treated for hepatoblastoma. 

    The study looked at children who had received platinum therapy followed by surgery to remove the tumor. The researchers sampled tissues from the liver — both healthy and cancerous — and the patient’s blood, analyzing them through a sophisticated DNA sequencing technique called NanoSeq. 

    They then compared the sequencing results to those from children who had been treated with different drugs, or had not been treated prior to surgery, as well as to fetal liver tissue. They found that being exposed to platinum agents led to hundreds of mutations in genes (on average 2,200 per liver sample), a burden of mutation usually found in adult livers. In other words, platinum aged the liver cells of treated children, making them look more like adult liver cells.

    Mutation load also increased proportionally to platinum exposure: children who received only cisplatin had a smaller number of mutations than those who received both cisplatin and carboplatin. These mutations could increase the likelihood of liver pathologies, or the emergence of secondary tumors, the authors said. 

    “We found lots of cancer genes but also genes associated with long-term changes in liver metabolism,” said Foad Rouhani, one of the authors of the paper and a professor at King’s College in London. However, he stressed that “by no means does that mean that these cells will definitely become cancerous in time. All we talk about is there was evidence for potential for these cells to eventually cause problems further down the line.” 

    Liver cells showed many more mutations than blood cells, even though chemotherapy is a systemic treatment. “The platinum is doing something differently to liver cells than other cells. Either it’s been metabolized differently or the liver cells are repairing differently, we don’t really know yet,” said Rouhani. This could mean that the liver was more susceptible to the effects of platinum, or it could be the other way around: The extent of the mutations may explain why that liver got sick in the first place. 

    In a perspective article, Sanjeev Vasudevan and Donald Williams Parsons, both professors at Baylor College of Medicine in Houston, wrote that the findings “provide strong evidence for conducting survivorship studies of children that have undergone treatment for liver cancer beyond their third decade of life.”

    For the study authors, its primary contribution lies in establishing that the damage occurs, so clinicians can monitor these patients more closely during their lifetimes, said Rouhani, and identify issues at an earlier stage. 

    But there could be a prospective impact on treatment. “If we understand the mechanism, can we then eventually be able to design next-generation chemotherapies which are highly effective at treating the cancer but actually leave the background tissue largely untouched?” said Rouhani.

  • STAT+: The Ig Nobel Prizes, long held in the U.S., head to Europe due to Trump policies

    STAT+: The Ig Nobel Prizes, long held in the U.S., head to Europe due to Trump policies

    By Allyson Chiu — Boston Globe

    Sept. 2, 2026

    It usually takes 10 minutes for Marc Abrahams, founder of the Ig Nobel Prizes, to walk from his home in Cambridge, Mass., to the annual award ceremony — a world-renowned spectacle celebrating quirky scientific achievements.

    But this year, Abrahams’s trip involves an international flight.

    For the first time since the awards — a satirical version of the Nobel prizes — were created in 1991, the ceremony, which takes place Thursday and draws hundreds of scientists and journalists from around the world, is not being held in Cambridge or Boston. Organizers said they decided to move the event to Zurich, Switzerland, due to concerns that many international participants, including award winners, would not feel comfortable or be able to come to the United States amid the Trump administration’s immigration crackdown and upending of science.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • STAT+: House votes to temporarily block Trump plan to politicize federal grants

    STAT+: House votes to temporarily block Trump plan to politicize federal grants

    Research policy was included in must-pass government funding bill

    Samuel Corum/Getty Images

    John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.

    Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16.

    WASHINGTON — The House voted Tuesday to pass a stopgap government-funding bill that temporarily blocks the White House’s proposal to give political appointees more control over federal research grants.

    The vote was 370-48 in favor. The Senate passed the same bill a month ago, so it now goes to the president for his signature. 

    The reprieve is brief. The bill funds the government until Dec. 11 to get past the midterm elections without a government shutdown, and the ban on the research-funding policy expires at the same time.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    1. John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.

    2. General Assignment Reporter

      Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16.

  • STAT+: Will House delay Trump plan to politicize NIH grants? 

    STAT+: Will House delay Trump plan to politicize NIH grants? 

    You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

    A New York bar sells a spritz in a Hermès-esque glass purse, while in Baltimore you can get a spritz made with Miller High Life beer. Way to keep it real, guys. Send news tips and your favorite cocktail of the Deadliest Drug to [email protected] or John_Wilkerson.07 on Signal.

    The need-to-know this week

    • The House returns for one week and will vote on the Senate’s stopgap funding bill that temporarily blocks the White House’s proposal to give political appointees control over federal research grants. The House will use a fast-track process that requires two-thirds support for passage, signaling that House GOP leadership believes the Senate bill will pass. The House vote is expected Tuesday evening, according to Punchbowl News. Were it to fail, lawmakers would have to wait until the Senate returns on Sept. 14 to work out differences between the two chambers’ bills.
    • Congressional Medicare advisers kick off their annual public meeting cycle on Thursday. This cycle, the Medicare Payment Advisory Commission will analyze the Part D benefit redesign. The redesign reduced cost sharing for beneficiaries and gave insurers more reason to manage costs, but it has probably also contributed to more spending. MedPAC also will study clinician quality measurements, and commissioners will continue their work on Medicare Advantage.

    Nine, or 10, more MFN deals

    President Trump announced nine more deals to set drug prices in Medicaid on par with prices available in peer countries, Daniel Payne and Elaine Chen report. But it seems they missed one.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • STAT+: NIH proposal to cap research grants draws mixed reception, agency says

    STAT+: NIH proposal to cap research grants draws mixed reception, agency says

    By Anil Oza

    Sept. 1, 2026

    General Assignment Reporter

    Under the Trump administration, competition for government funding for biomedical research has reached new heights. In June, the National Institutes of Health proposed one solution: limiting the number of grants each individual scientist can have at a given moment. 

    The agency recently released the anonymized 3,307 responses to its call for feedback, and it appears the proposal has drawn more mixed reactions than earlier such proposals. The NIH estimates that 40% of the responses opposed the proposal, 27% supported the idea of a cap, and 32% were mixed. 

    In a post on its site, the agency said it hopes a cap could “contribute to a more balanced research portfolio, advancing stewardship, workforce sustainability, and the goals of the NIH Unified Funding Strategy.” But even some experts who agree with the spirit of the proposal worry that it could be another source of disruption for researchers in what has been a tumultuous time; some also argue that a straight cap on the number of grants may be too simplistic. 

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe